Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Short-term Investments (2016 - 2021)

Aytu Biopharma (AYTU) has disclosed Short-term Investments for 6 consecutive years, with $252000.0 as the latest value for Q3 2021.

  • On a quarterly basis, Short-term Investments changed 0.0% to $252000.0 in Q3 2021 year-over-year; TTM through Sep 2021 was $252000.0, a 0.0% change, with the full-year FY2021 number at $252000.0, changed 0.4% from a year prior.
  • Short-term Investments was $252000.0 for Q3 2021 at Aytu Biopharma, roughly flat from $252000.0 in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $252000.0 in Q3 2020 to a low of $75214.0 in Q2 2017.
  • A 5-year average of $195549.0 and a median of $250500.0 in 2019 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 92.78% in 2017, then surged 150.83% in 2019.
  • Aytu Biopharma's Short-term Investments stood at $75214.0 in 2017, then skyrocketed by 33.25% to $100225.0 in 2018, then soared by 150.83% to $251396.0 in 2019, then rose by 0.24% to $252000.0 in 2020, then changed by 0.0% to $252000.0 in 2021.
  • Per Business Quant, the three most recent readings for AYTU's Short-term Investments are $252000.0 (Q3 2021), $252000.0 (Q2 2021), and $252000.0 (Q4 2020).